[HTML][HTML] rAAV-mediated tumorigenesis: still unresolved after an AAV assault
Molecular Therapy, 2012•cell.com
The two parameters that define this risk are integration site preference and frequency of
integration. Recombinant adeno-associated viral (rAAV) vectors have been shown to be
safe and efficacious in early gene therapy clinical trials, 1–4 although such vectors do
integrate into the genome at a low but measureable rate (0.1 to 1% of transduction events) in
animal models. 5, 6 In this issue of Molecular Therapy, Rosas and colleagues test various
conditions that are hypothesized to facilitate rAAV integration so as to determine whether …
integration. Recombinant adeno-associated viral (rAAV) vectors have been shown to be
safe and efficacious in early gene therapy clinical trials, 1–4 although such vectors do
integrate into the genome at a low but measureable rate (0.1 to 1% of transduction events) in
animal models. 5, 6 In this issue of Molecular Therapy, Rosas and colleagues test various
conditions that are hypothesized to facilitate rAAV integration so as to determine whether …
The two parameters that define this risk are integration site preference and frequency of integration. Recombinant adeno-associated viral (rAAV) vectors have been shown to be safe and efficacious in early gene therapy clinical trials, 1–4 although such vectors do integrate into the genome at a low but measureable rate (0.1 to 1% of transduction events) in animal models. 5, 6 In this issue of Molecular Therapy, Rosas and colleagues test various conditions that are hypothesized to facilitate rAAV integration so as to determine whether these events can lead to an increased rate of oncogenesis. 7
cell.com